The following is an FDA safety communication regarding updated warnings for RSV vaccines Abrysvo and Arexvy. FDA Safety Communication Purpose: To inform the public and healthcare providers that FDA has required and approved safety labeling changes to the Prescribing Information for […]
FDA alert: Warning added to RSV vaccines for Guillain-Barré risk Read More »
The following is from The Vaccine Reaction. On Feb. 29, 2024, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) presented a preliminary analysis that showed that 23 adults over the age of 65
CDC Preliminary Analysis: RSV vaccines for seniors linked to Guillain-Barré Syndrome Read More »
The following is an excerpt from MedPage Today. In two somewhat close votes, an FDA panel of outside experts recommended the agency approve Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, despite concerns over the potential risk for Guillain
FDA green lights new Pfizer RSV vaccine amid safety concerns Read More »
